CClinicalTrials.gg
Sign In
Active, not recruitingNCT01796145Updated Nov 17, 2025

Fibroscan Study in HCC

An interventional study of Fibroscan in Confirmed Diagnosis of Hepatocellular Carcinoma, Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery and Child's A to C Cirrhosis, sponsored by Chinese University of Hong Kong. Active, not recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
207
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC

02

Conditions studied

  • Confirmed Diagnosis of Hepatocellular Carcinoma
  • Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery
  • Child's A to C Cirrhosis
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of HCC

  • Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery

    1. For TACE cohort, patients undergoing first cycle TACE are eligible.
    2. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible.
    3. For surgery cohort, patient undergoing surgery are eligible.
  • Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed
  • Child's A to Child's C liver function

Exclusion criteria

Exclusion Criteria:

  • ECOG performance status > 2
  • Poorly controlled ascites
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    TACE

    Other: Fibroscan

  • Experimental
    Systemic Therapy

    Other: Fibroscan

  • Experimental
    Surgery

    Other: Fibroscan

Interventions

  • OtherFibroscan
06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: 3 years

Secondary outcomes

  1. Rate and grade of treatment complications

    Time frame: 2 years

  2. Liver stiffness (kPa)

    Time frame: 2 years

07

Study locations

1 site
  • Department of Clinical Oncology, Prince of Wales Hospital
    Hong Kong, Hong Kong
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01796145
Lead sponsor
Chinese University of Hong Kong
Responsible party
CCTU (Comprehensive Cancer Trials Unit, Chinese University of Hong Kong) — Principal investigator
First posted
Feb 21, 2013
Start date
Feb 27, 2013
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Stephen Lam Chan, FHKCP
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Chinese University of Hong Kong

Start the discussion